Chrispijn, M.

liver month lanreotide volume 12 months liver volume patient treatment 6 months kidney kidney volume change polycystic trial lanreotide treatment study polycystic liver disease disease effect aliment pharmacol somatostatin analogues adpkd radboud university nijmegen polycystic liver volume signi ficant change polycystic kidney disease figure somatostatin result follow-up bene ficial effect nijmegen placebo pharmacol aliment university therapy analogue department centre symptom table signi octreotide polycystic liver patients cohort publishing hepatology blackwell hepatic university hospital gasthuisberg health 266–274 netherland baseline extension adpkd patients growth autosomal responder observation randomised outcome decrease safety ficant increase chrispijn polycystic kidneys gastroenterology liver transplantation value lanreotide 120 mg drenth times uln volumetry quality kidney volumes lmol ⁄ l liver volumes